Developer docs
API playgroundTry for free, no card

Search company profiles

Jellatech

Full company profile

uuid0000fpw

Namestring
Jellatech
Legal namestring
Jellatech Inc.
Websiteurl
jellatech.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Jellatech is a North Carolina-based B2B biotechnology company founded in 2020 that produces bio-identical collagen through cellular agriculture. The company's proprietary platform uses mammalian cell culture to manufacture full-length, triple-helical collagen structurally identical to native human collagen, requiring only a one-time 3mm skin biopsy to establish scalable, proprietary cell lines. Its core product is Human Type I Atelo-Collagen, currently offered for research-use-only with greater than 95% purity, ~300 kDa molecular weight, and telopeptide regions removed for reduced immunogenicity; a Human Type I Telo-Collagen variant with intact telopeptides is in development for applications requiring higher fibrillogenesis. The platform has previously demonstrated translatability to bovine and porcine collagen variants.

The business operates as a B2B supplier with a quote-based direct sales model targeting enterprise customers across biomedical and health, pharmaceutical, research and development, beauty and personal care, materials and processes, and food and beverage verticals. Stated use cases include tissue engineering, regenerative medicine, 3D bioprinting, dermal fillers, cell and gene therapy, drug delivery, wound healing, and cosmetic formulations. Jellatech began commercial sample deliveries in December 2024 and January 2025 with ongoing monthly sample production. The company is led by Founder and CEO Stephanie Michelsen and is venture-backed with approximately $5.5 million raised across pre-seed ($2M, April 2021) and seed ($3.5M, August 2023 led by byFounders) rounds. It is in an early commercialization phase, with a new 9,000 sq ft Morrisville, NC facility (occupied November 2024) targeted for GLP certification by 2026 to support clinical- and industrial-grade biomedical supply.

Short descriptiontext

Jellatech is a B2B biotechnology company producing bio-identical human Type I collagen through cellular agriculture. The Raleigh, NC-based firm supplies triple-helical collagen to biomedical, pharmaceutical, research, and personal care customers via a quote-based direct sales model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRaleigh, United States
HQ citystring
Raleigh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bio-identical collagen production, cellular agriculture platform, animal-free proteins, human collagen manufacturing, biotech B2B supplies
Industry4 codes
PRIMARYAFAJAHAL
Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAKAGAI
Cultivated (Cell-Based) Protein Foods Manufacturing
Agriculture & Food Production/Food Processing & Manufacturing/Plant-Based & Alternative Protein Foods Manufacturing
SECONDARYCRADAOAJ
Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids)
SECONDARYAFANAGAI
Collagen, Gelatin & Protein Hydrolysates (Animal-Derived)
Agriculture & Food Production/Meat, Poultry & Seafood Processing/Rendering & By-Product Processing (Tallow, Meat & Bone Meal, Pet Food Inputs)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Food Manufacturing311
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Food And Kindred Products2000
Product category
Bio-identical Collagen Manufacturing
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Bio-identical Collagen Protein Sales
TypeOne Time License
Description

Jellatech generates revenue through the sale of its cell-cultured, bio-identical human Type I collagen products to B2B customers in biomedical, pharmaceutical, medical aesthetics, and research sectors. Products are offered in research-use-only formats, with future plans for clinical- and industrial-grade biomaterials. The company operates on a quote-based, direct sales model targeting enterprise buyers.

jellatech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Jellatech develops and sells bio-identical human Type I collagen (and other complex proteins) produced via proprietary cellular agriculture and synthetic biology. Products are supplied as research-use-only collagen materials—currently Human Type I Atelo-Collagen with telopeptide regions removed—alongside a pipeline of Telo-Collagen variants, targeting B2B customers in biomedical, pharmaceutical, medical aesthetics, research, beauty/personal care, and food & beverage sectors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Collagen purity >95% achieved through proprietary purification methodology
+2 more records
Product overview1 text field

Jellatech is a biotechnology company producing bio-identical complex proteins through cellular agriculture and synthetic biology. The company's product portfolio centers on Human Type I Collagen, offered in two variants: Human Type I Atelo-Collagen (currently available for research use, with telopeptide regions removed for superior biocompatibility) and Human Type I Telo-Collagen (in development, with intact telopeptides for enhanced mechanical integrity). Both products are produced via the company's proprietary cellular agriculture platform, which creates scalable, ethical, animal-free collagen identical to native human tissue-derived collagen. The platform previously supported bovine and porcine collagen development and has expanded to focus on human collagen for biomedical applications including regenerative medicine, medical aesthetics, tissue engineering, and therapeutic solutions.

Product and service2 records
1Human Type I Atelo-Collagen
CategoryBio-identical collagen protein (research-grade)
Description

Highly purified (>95%), full-length, triple-helical human Type I collagen with telopeptide regions removed for superior biocompatibility and reduced immunogenicity. Currently offered for research-use only, targeting cell culture models, drug delivery systems, and injectable biomaterials, with ~300 kDa molecular weight and verified triple-helix integrity.

2Human Type I Telo-Collagen
CategoryBio-identical collagen protein (in development)
Description

Human Type I telo-collagen with intact telopeptide regions offering exceptional biomimicry and mechanical integrity, with preserved telopeptides enabling superior fibrillogenesis and tissue integration for applications requiring full tissue mimicry.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Matthew Kane
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-03
Description

Matthew Kane, CEO of Celyad Oncology and former CEO of Tune Therapeutics and Precision BioSciences, joined Jellatech's advisory board. He brings over two decades of biotechnology expertise including raising over $100M and leading initiatives that raised over $400M in funding and formed partnerships exceeding $4.7B in value. His expertise supports Jellatech's commercial strategy, licensing, and therapeutic applications.

jellatech.com
2Dr. Bill Polacheck
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-03
Description

Dr. Bill Polacheck, Assistant Professor in the Joint Department of Biomedical Engineering at UNC and NC State and Cell Biology and Physiology at UNC School of Medicine, joined Jellatech's advisory board. His expertise in biomechanics, extracellular proteins, 3D microfluidics, and human tissue modeling accelerates Jellatech's advancements in human tissue modeling and collagen innovation.

jellatech.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-15
Description

Ryan Bethencourt, CEO of Wild Earth Inc., serves on Jellatech's board of directors, contributing strategic guidance on sustainable biotechnology and alternative protein commercialization.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-15
Description

Peter Andersen, Chief Research & Development Officer at TreeFrog Therapeutics, serves on Jellatech's board of directors, providing R&D strategy expertise in cell-based protein production.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Geltor is the most direct competitor to Jellatech: it produces animal-free, bio-identical collagen and other proteins via precision fermentation and cell-based processes for beauty, nutrition, and biomedical applications. Both target the same B2B opportunity of replacing animal-derived collagen with cell-cultured alternatives.

TypeDirect peer
Description

Modern Meadow applies biofabrication and cellular agriculture to produce bio-based leather and protein materials, including collagen-like proteins for biomedical applications. Comparable to Jellatech in its use of cellular agriculture for complex protein production at B2B scale.

3Gelita
TypeBroad incumbent
Description

Gelita is one of the world's largest producers of gelatin and collagen peptides from animal sources, serving pharma, nutrition, and technical applications. It is the dominant incumbent whose supply chain Jellatech is directly competing to disrupt.

TypeBroad incumbent
Description

Rousselot is a global leader in gelatin and collagen-based solutions for food, pharma, and nutrition, owned by Darling Ingredients. It represents the established, at-scale animal-derived competitor that Jellatech must displace in biomedical and F&B accounts.

TypeBroad incumbent
Description

PB Leiner is a major global gelatin and collagen producer serving food, pharma, and technical applications. As an incumbent with industrial-scale capacity, it is a direct baseline competitor against which Jellatech's bio-identical positioning must justify premium pricing.

6Nitta Gelatin
TypeBroad incumbent
Description

Nitta Gelatin is a Japan-based established collagen and gelatin manufacturer with global biomedical and food ingredient reach. Comparable to Jellatech as a collagen supplier to pharma/biomedical end markets, but with a much larger installed base.

TypeEmerging player
Description

Perfect Day uses precision fermentation to produce animal-free dairy proteins and is expanding its cell-based protein platform to adjacent ingredients. Comparable to Jellatech as a capital-intensive alternative-protein challenger using synthetic biology at industrial scale.

TypeEmerging player
Description

Motif FoodWorks develops animal-free protein ingredients using fermentation and food science for meat and dairy alternatives. It overlaps with Jellatech in applying cellular/synthetic biology to develop B2B alternative protein ingredients for the food industry.

TypeEmerging player
Description

Believer Meats (formerly Future Meat Technologies) is a cultivated meat company using cellular agriculture to produce animal cell-grown meat products. Comparable to Jellatech in core cellular agriculture technology stack, though applied to a different end product category.

TypeEmerging player
Description

Cellva Ingredients is a Brazilian cellular agriculture company producing animal-free fats and functional ingredients via cell cultivation. It is comparable to Jellatech as an emerging player applying cell-cultivation technology to produce B2B specialty food/biotech ingredients.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jellatech

Bio-identical Collagen Manufacturingjellatech.com

Jellatech is a B2B biotechnology company producing bio-identical human Type I collagen through cellular agriculture. The Raleigh, NC-based firm supplies triple-helical collagen to biomedical, pharmaceutical, research, and personal care customers via a quote-based direct sales model.

What Jellatech does

Jellatech is a North Carolina-based B2B biotechnology company founded in 2020 that produces bio-identical collagen through cellular agriculture. The company's proprietary platform uses mammalian cell culture to manufacture full-length, triple-helical collagen structurally identical to native human collagen, requiring only a one-time 3mm skin biopsy to establish scalable, proprietary cell lines. Its core product is Human Type I Atelo-Collagen, currently offered for research-use-only with greater than 95% purity, ~300 kDa molecular weight, and telopeptide regions removed for reduced immunogenicity; a Human Type I Telo-Collagen variant with intact telopeptides is in development for applications requiring higher fibrillogenesis. The platform has previously demonstrated translatability to bovine and porcine collagen variants.

The business operates as a B2B supplier with a quote-based direct sales model targeting enterprise customers across biomedical and health, pharmaceutical, research and development, beauty and personal care, materials and processes, and food and beverage verticals. Stated use cases include tissue engineering, regenerative medicine, 3D bioprinting, dermal fillers, cell and gene therapy, drug delivery, wound healing, and cosmetic formulations. Jellatech began commercial sample deliveries in December 2024 and January 2025 with ongoing monthly sample production. The company is led by Founder and CEO Stephanie Michelsen and is venture-backed with approximately $5.5 million raised across pre-seed ($2M, April 2021) and seed ($3.5M, August 2023 led by byFounders) rounds. It is in an early commercialization phase, with a new 9,000 sq ft Morrisville, NC facility (occupied November 2024) targeted for GLP certification by 2026 to support clinical- and industrial-grade biomedical supply.

Jellatech firmographics

Firmographics
Name
Jellatech
Legal name
Jellatech Inc.
Website
https://jellatech.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Jellatech is a B2B biotechnology company producing bio-identical human Type I collagen through cellular agriculture. The Raleigh, NC-based firm supplies triple-helical collagen to biomedical, pharmaceutical, research, and personal care customers via a quote-based direct sales model.
Ownership category
akta.pro rank

Jellatech industry classification

Industry
Product category
Bio-identical Collagen Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Food Manufacturing (311)
SIC
Biological Products, (No Disgnostic Substances) (2836), Food And Kindred Products (2000)
akta.pro industry
PRIMARYAFAJAHAL
Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAKAGAI
Cultivated (Cell-Based) Protein Foods Manufacturing
Agriculture & Food Production/Food Processing & Manufacturing/Plant-Based & Alternative Protein Foods Manufacturing
SECONDARYCRADAOAJ
Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids)
SECONDARYAFANAGAI
Collagen, Gelatin & Protein Hydrolysates (Animal-Derived)
Agriculture & Food Production/Meat, Poultry & Seafood Processing/Rendering & By-Product Processing (Tallow, Meat & Bone Meal, Pet Food Inputs)

Keywords

  • Bio-identical collagen production
  • Cellular agriculture platform
  • Animal-free proteins
  • Human collagen manufacturing
  • Biotech B2B supplies

Where Jellatech is headquartered

Location

Headquarters

HQ city
Raleigh
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Jellatech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Bio-identical Collagen Protein Sales: Jellatech generates revenue through the sale of its cell-cultured, bio-identical human Type I collagen products to B2B customers in biomedical, pharmaceutical, medical aesthetics, and research sectors. Products are offered in research-use-only formats, with future plans for clinical- and industrial-grade biomaterials. The company operates on a quote-based, direct sales model targeting enterprise buyers.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Jellatech product offering

Product offering

Core offering

Jellatech develops and sells bio-identical human Type I collagen (and other complex proteins) produced via proprietary cellular agriculture and synthetic biology. Products are supplied as research-use-only collagen materials—currently Human Type I Atelo-Collagen with telopeptide regions removed—alongside a pipeline of Telo-Collagen variants, targeting B2B customers in biomedical, pharmaceutical, medical aesthetics, research, beauty/personal care, and food & beverage sectors.

Product overview

Jellatech is a biotechnology company producing bio-identical complex proteins through cellular agriculture and synthetic biology. The company's product portfolio centers on Human Type I Collagen, offered in two variants: Human Type I Atelo-Collagen (currently available for research use, with telopeptide regions removed for superior biocompatibility) and Human Type I Telo-Collagen (in development, with intact telopeptides for enhanced mechanical integrity). Both products are produced via the company's proprietary cellular agriculture platform, which creates scalable, ethical, animal-free collagen identical to native human tissue-derived collagen. The platform previously supported bovine and porcine collagen development and has expanded to focus on human collagen for biomedical applications including regenerative medicine, medical aesthetics, tissue engineering, and therapeutic solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Human Type I Atelo-Collagen Highly purified (>95%), full-length, triple-helical human Type I collagen with telopeptide regions removed for superior biocompatibility and reduced immunogenicity. Currently offered for research-use only, targeting cell culture models, drug delivery systems, and injectable biomaterials, with ~300 kDa molecular weight and verified triple-helix integrity.
  • Human Type I Telo-Collagen Human Type I telo-collagen with intact telopeptide regions offering exceptional biomimicry and mechanical integrity, with preserved telopeptides enabling superior fibrillogenesis and tissue integration for applications requiring full tissue mimicry.

Quantifiable outcome

  • Collagen purity >95% achieved through proprietary purification methodology
  • +2 more outcomes

Companies that use Jellatech

Customer profile

Segments5 records

Ideal customer profiles5 records

Jellatech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Jellatech partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Matthew KanecoreStrategic or Co-development Partner · 3 December 2024Matthew Kane, CEO of Celyad Oncology and former CEO of Tune Therapeutics and Precision BioSciences, joined Jellatech's advisory board. He brings over two decades of biotechnology expertise including raising over $100M and leading initiatives that raised over $400M in funding and formed partnerships exceeding $4.7B in value. His expertise supports Jellatech's commercial strategy, licensing, and therapeutic applications.
  • Dr. Bill PolacheckcoreStrategic or Co-development Partner · 3 December 2024Dr. Bill Polacheck, Assistant Professor in the Joint Department of Biomedical Engineering at UNC and NC State and Cell Biology and Physiology at UNC School of Medicine, joined Jellatech's advisory board. His expertise in biomechanics, extracellular proteins, 3D microfluidics, and human tissue modeling accelerates Jellatech's advancements in human tissue modeling and collagen innovation.
  • Ryan BethencourtminorStrategic or Co-development Partner · 15 October 2024Ryan Bethencourt, CEO of Wild Earth Inc., serves on Jellatech's board of directors, contributing strategic guidance on sustainable biotechnology and alternative protein commercialization.
  • Peter AndersenminorStrategic or Co-development Partner · 15 October 2024Peter Andersen, Chief Research & Development Officer at TreeFrog Therapeutics, serves on Jellatech's board of directors, providing R&D strategy expertise in cell-based protein production.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Jellatech competitors and assessment

Company assessment

Direct peers

  • Geltor: Geltor is the most direct competitor to Jellatech: it produces animal-free, bio-identical collagen and other proteins via precision fermentation and cell-based processes for beauty, nutrition, and biomedical applications. Both target the same B2B opportunity of replacing animal-derived collagen with cell-cultured alternatives.
  • Modern Meadow: Modern Meadow applies biofabrication and cellular agriculture to produce bio-based leather and protein materials, including collagen-like proteins for biomedical applications. Comparable to Jellatech in its use of cellular agriculture for complex protein production at B2B scale.

Broad incumbents

  • Gelita: Gelita is one of the world's largest producers of gelatin and collagen peptides from animal sources, serving pharma, nutrition, and technical applications. It is the dominant incumbent whose supply chain Jellatech is directly competing to disrupt.
  • Rousselot: Rousselot is a global leader in gelatin and collagen-based solutions for food, pharma, and nutrition, owned by Darling Ingredients. It represents the established, at-scale animal-derived competitor that Jellatech must displace in biomedical and F&B accounts.
  • PB Leiner: PB Leiner is a major global gelatin and collagen producer serving food, pharma, and technical applications. As an incumbent with industrial-scale capacity, it is a direct baseline competitor against which Jellatech's bio-identical positioning must justify premium pricing.
  • Nitta Gelatin: Nitta Gelatin is a Japan-based established collagen and gelatin manufacturer with global biomedical and food ingredient reach. Comparable to Jellatech as a collagen supplier to pharma/biomedical end markets, but with a much larger installed base.

Emerging players

  • Perfect Day: Perfect Day uses precision fermentation to produce animal-free dairy proteins and is expanding its cell-based protein platform to adjacent ingredients. Comparable to Jellatech as a capital-intensive alternative-protein challenger using synthetic biology at industrial scale.
  • Motif FoodWorks: Motif FoodWorks develops animal-free protein ingredients using fermentation and food science for meat and dairy alternatives. It overlaps with Jellatech in applying cellular/synthetic biology to develop B2B alternative protein ingredients for the food industry.
  • Believer Meats: Believer Meats (formerly Future Meat Technologies) is a cultivated meat company using cellular agriculture to produce animal cell-grown meat products. Comparable to Jellatech in core cellular agriculture technology stack, though applied to a different end product category.
  • Cellva Ingredients: Cellva Ingredients is a Brazilian cellular agriculture company producing animal-free fats and functional ingredients via cell cultivation. It is comparable to Jellatech as an emerging player applying cell-cultivation technology to produce B2B specialty food/biotech ingredients.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Jellatech social profiles

Digital presence

Jellatech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jellatech leadership team

Management profile

Number of profiles

Profiles8 records

Jellatech funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jellatech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jellatech

What does Jellatech do?

Jellatech develops and sells bio-identical human Type I collagen (and other complex proteins) produced via proprietary cellular agriculture and synthetic biology. Products are supplied as research-use-only collagen materials—currently Human Type I Atelo-Collagen with telopeptide regions removed—alongside a pipeline of Telo-Collagen variants, targeting B2B customers in biomedical, pharmaceutical, medical aesthetics, research, beauty/personal care, and food & beverage sectors.

Is Jellatech a public or private company?

Jellatech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Jellatech founded?

Jellatech was founded in 2020. It employs 1 to 10 people.

Where is Jellatech based?

Jellatech is headquartered in Raleigh, United States, in the North America region.

How does Jellatech make money?

One revenue line is on record: bio-identical Collagen Protein Sales.

Who are Jellatech's main competitors?

Direct peers on record are Geltor and Modern Meadow. Broad incumbents are Gelita, Rousselot, PB Leiner and Nitta Gelatin. Emerging players are Perfect Day, Motif FoodWorks, Believer Meats and Cellva Ingredients.

Does Jellatech have an API?

No public API is recorded for Jellatech.

What industry is Jellatech in?

Jellatech's product category is Bio-identical Collagen Manufacturing. Its primary akta.pro industry code is AFAJAHAL, Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins), with a secondary code of AFAKAGAI, Cultivated (Cell-Based) Protein Foods Manufacturing. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NC BiotechBioreactors, Not Boiling Vats: How Jellatech Plans to Stir Up the Collagen SectorJellatech, a Raleigh-based startup founded by Stephanie Michelsen and Kylie Hesp, is developing an animal-free collagen production process using fibroblasts cultured in bioreactors. The company recently secured a $2 million pre-seed investment round to expand its R&D efforts and scale operations from its current small office in the Research Triangle.JoyfulCollagen Redefined: Joyful Ventures Invests in Jellatech's Sustainable Protein SolutionJoyful Ventures and byFounders led a $3.5 million oversubscribed Seed Round for Jellatech, a Raleigh-based biotech company specializing in sustainable, animal-free protein production via cellular agriculture. The funding will support Jellatech's research, development, and commercialization efforts to reduce the environmental impact of traditional collagen manufacturing.YahooCULT Food Science Venture Arm Company Jellatech Included in New Bezos Earth Fund Research Centre at N.C. StateJellatech, a cellular agriculture venture arm, will join the Bezos Earth Fund's $30M research center at N.C. State. The center aims to advance sustainable protein production, and Jellatech's collagen production aligns with its mission. CULT Food Science, an investor in Jellatech, sees potential for growth from this collaboration.YahooCULT Food Science Venture Arm Company Jellatech Included in New Bezos Earth Fund Research Centre at N.C. StateJellatech, a cellular agriculture company, was selected to participate in the Bezos Earth Fund's $30M research center at North Carolina State University. The center aims to advance sustainable protein production, and Jellatech's collagen production aligns with its mission. CULT Food Science, an investor in Jellatech, sees potential for growth from this collaboration.foodnavigator.comAnimal-free collagen: The food and drink potentialThe collagen market is projected to grow from $5.1bn in 2023 to $7.4bn by 2030, with plant-based alternatives like VeCollal and Jellatech emerging. These alternatives claim lower environmental footprints, and food and drink applications are expected to expand, though regulatory approval remains a hurdle.foodnavigator.comHow is animal-free collagen made and does it work?Animal-free collagen is produced via cellular agriculture (Jellatech) and plant-based biomimetic methods (VeCollal, ProTec Nutra). VeCollal's plant-based collagen showed 32.9% wrinkle reduction in a trial, while Jellatech's cell-based collagen is not yet on the market.SecSEC FORM DJellatech, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt securities offering under Rule 506(b). The company raised a total of $3,500,000 from eight investors, with sales commencing on August 23, 2023. This regulatory filing discloses the private placement details for the biotechnology firm based in Raleigh, North Carolina.TechCrunchDeal Dive: A cellular ag startup with a real moatJellatech, a cellular agriculture startup founded in 2020 by Stephanie Michelsen, has secured a $3.5 million seed round led by byFounders VC, with participation from Milano Investment Partners and Joyful VC. The company distinguishes itself from meat-focused cellular agriculture startups by producing lab-grown collagen and gelatin for industries beyond food, including personal care, beauty, biomedicine, and materials. Michelsen identified animal byproducts like collagen as an overlooked opportunity in the alternative protein space, allowing the company to pursue multiple revenue streams and regulatory pathways.FinSMEsJellatech Raises $3.5M in Seed FundingJellatech, a biotechnology company based in Raleigh, NC, raised $3.5 million in seed funding led by byFounders with participation from other investors including Milano Investment Partners and Joyful VC. The company intends to utilize these funds to advance its research and development efforts for complex proteins produced via cellular agriculture. This capital injection aims to scale up processes, expand the scientific team, and accelerate commercialization across industries such as food, materials, and biomedicine.American City Business JournalsHow Raleigh startup Jellatech is reinventing collagen for biopharma, food and cosmeticsRaleigh biotech Jellatech grew enough lab-cultured collagen to see with the naked eye, a milestone in its two-year development. The company raised $2 million last year and plans to scale production, targeting biopharma, cosmetics, and food. It expects commercial contracts within two to three years.